MapLight Therapeutics, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $225M in Series C funding.
The round was led by Novo Holdings, 5AM Ventures, Cowen Healthcare Investments and other investors.
In connection with the financing, Jim Trenkle, Ph.D., MBA, Partner in the Venture Investments group at Novo Holdings will join the MapLight Therapeutics Board of Directors.
Led by CEO and Founder Christopher Kroeger, MapLight is working to develop targeted, novel therapeutics to improve the lives of people with difficult-to-treat brain disorders. Its discovery platform uses proprietary technologies to uncover the individual circuits that misfire in brain disorders and target those circuits with effective, safe therapeutics.
This round will advance ML-007C-MA, a novel M1/M4 muscarinic agonist agent combined with a precision matched peripheral muscarinic antagonist, into Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis in 2024, and enable continued progress on the company’s other pipeline programs.
In addition to ML-007C-MA, MapLight currently has two other products in clinical development: ML-007 is under study for dyskinesia, and ML-004, a 5HT-1b agonist is currently in Phase 2 for social communication deficits in patients with autism spectrum disorder. The company’s pipeline preclinical assets include ML-016, a GPR-6 antagonist under study for both Parkinson’s disease and depression, and ML-009, in development to treat hyperactivity and impulsivity.
FinSMEs
30/10/2023